首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Cardiac pacemakers in pediatric heart transplant recipients: incidence, indications, and associated factors. Pediatric Heart Transplant Group-Loma Linda.
【24h】

Cardiac pacemakers in pediatric heart transplant recipients: incidence, indications, and associated factors. Pediatric Heart Transplant Group-Loma Linda.

机译:小儿心脏移植受者的心脏起搏器:发生率,适应症及相关因素。小儿心脏移植小组-Loma Linda。

获取原文
获取原文并翻译 | 示例
       

摘要

This study was undertaken to assess the incidence, indications, and predisposing factors for pacemaker placement in a pediatric heart transplant population. From November 1985 to May 1994, 246 pediatric patients have undergone cardiac transplantation at Loma Linda University Medical Center. Seven (2.8%) have received pacemaker placement with an 8-50 month follow-up period. Median age at transplant was 462 days (0 days to 2.5 years). The median time to pacemaker placement was 190 days (18-1,672 days) after transplantation. Indications were sick sinus syndrome (SSS) in 5 and heart block in 2 patients (1 during acute rejection). Three patients with SSS underwent electrophysiology studies (EPS); 1 was normal and 2 showed sinus node dysfunction. The mode of pacing was VVIR in 6 patients and VVI in 1 patient. All 6 survivors are doing well and 5 patients' pacemakers still provide support. These 7 patients were compared with 185 pediatric patients (0 days to 12-years-old) transplanted during 1985 through 1993who survived at least 6 months after transplantation. There was no correlation between the receipt of a pacemaker and graft cold ischemic time, rejection history, donor age, or recipient age at transplantation. The 5 patients with SSS had significantly lower average heart rates in the first month after transplantation (108 +/- 16 vs 130 +/- 12; P = 0.0002). The need for permanent pacemakers in this population is uncommon. Pacemakers, however, can be safely performed when necessary with excellent clinical results.
机译:进行这项研究是为了评估在小儿心脏移植人群中起搏器放置的发生率,适应症和诱发因素。 1985年11月至1994年5月,在Loma Linda大学医学中心对246名儿科患者进行了心脏移植。七名(2.8%)已接受起搏器植入,随访期为8-50个月。移植时的中位年龄为462天(0天至2.5岁)。植入心脏起搏器的中位时间为移植后190天(18-1,672天)。适应症为5例病态窦房结综合征(SSS)和2例患者心脏阻滞(急性排斥反应中1例)。 3名SSS患者接受了电生理研究(EPS); 1例正常,2例显示窦房结功能障碍。起搏方式为VVIR 6例,VVI 1例。所有6名幸存者都表现良好,而5名患者的起搏器仍在提供支持。将这7例患者与1985年至1993年间移植的至少存活6个月的185例小儿患者(0天至12岁)进行了比较。起搏器的接受与移植物冷缺血时间,排斥反应史,供体年龄或移植时受体年龄之间没有相关性。 5例SSS患者在移植后的第一个月平均心率明显降低(108 +/- 16比130 +/- 12; P = 0.0002)。在这种人群中,永久性起搏器的需求很少见。但是,起搏器可以在必要时安全进行,并具有出色的临床效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号